43
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Combined photodynamic therapy and intravitreal bevacizumab as treatment for nonresponsive myopic choroidal neovascularization

      letter
      Oman Journal of Ophthalmology
      Medknow Publications

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Sir, We report the efficacy of combination therapy using photodynamic therapy (PDT) and intravitreal bevacizumab for resistant choroidal neovascular membrane (CNVM) associated with myopia. A 59-year-old man presented with decreased vision in the left eye since 10 days. He did not have any systemic complaints. On examination, his best-corrected visual acuity was 6/18 in the right eye and 6/12 in the left eye. Anterior segment examination of both eyes was unremarkable, but for pseudophakia. Intraocular pressure in both the eyes was 15 mmHg. Fundus examination in right eye showed a myopic disc, rest of the fundus was within normal limits. Fundus examination in left eye showed myopic disc with subretinal hemorrhage. Fundus Fluorescein Angiography (FFA) [Figure 1a] and Optical Coherence Tomography (OCT) [Figure 2a] of the left eye confirmed the presence of juxtafoveal CNVM. The patient underwent PDT as per standard protocol and intravitreal injection of triamcinolone 2 days later. Figure 1 Serial Fundus Fluorescein Angiography (FFA) showing decrease in leakage at the area of choroidal neovascular membrane Figure 2 Serial Optical Coherence Tomography (OCT) showing decrease in retinal thickness with restoration of normal foveal contour At 1-month follow-up visit, his best-corrected visual acuity was decreased to 6/24 in left eye with the presence of persistent activity on FFA [Figure 1b] and retinal thickening on OCT [Figure 2b]. Combination therapy using PDT with anti-vascular endothelial growth factor (VEGF) was considered. Patient underwent PDT followed by intravitreal bevacizumab (1.25 mg) injection, 2 days later. No treatment-related adverse effect was noted. At the 1-month follow-up visit, his best-corrected visual acuity had improved to 6/9 in left eye, but FFA showed persistent activity. A second injection of intravitreal bevacizumab was performed. At the 2-month follow-up visit, his visual acuity was maintained at 6/9 with no activity on FFA. He has been on regular follow-up with stable fundus findings. At the 1-year follow-up visit, his visual acuity was maintained at 6/9 with scarred CNVM clinically and no activity on FFA [Figure 1c] with normal foveal contour on OCT [Figure 2c]. Patient was advised home Amsler’s monitoring and review after 4 months. Combination therapy plays a synergistic effect in the treatment of choroidal neovascularization. The combined regime is postulated to be beneficial in reducing the need for cyclic injections.[1] VEGF inhibition alone can prevent neovascularization at an early stage. However, once neovascular beds are established, they are unlikely to regress with anti-VEGF therapy alone. At this stage, a combined approach using a non-thermal laser has been seen to be beneficial.[2] Our patient did not respond to intravitreal triamcinolone with PDT, but showed significant improvement after subsequent administration of two injections of intravitreal bevacizumab along with PDT. Intravitreal bevacizumab alone has been reported to show better results compared to PDT.[3] Combination therapy with PDT could be considered as a better alternative to intravitreal bevacizumab alone, to reduce the number of injections and maintain the success for the long term, specially in resistant cases.

          Related collections

          Most cited references3

          • Record: found
          • Abstract: found
          • Article: not found

          Rationale for combination therapies for choroidal neovascularization.

          To provide a conceptual framework for the development and use of combination therapies for choroidal neovascularization secondary to age-related macular degeneration. Literature review, integration of data, and creation of hypothesis. An assessment of angiogenesis, cancer therapy, and inflammation was performed as they may pertain to choroidal neovascularization. A conceptual framework was created in which therapies for choroidal neovascularization could be evaluated alone or in combination. Angiogenesis occurs because cells produce angiogenic stimuli to encourage blood vessels to develop. This growth of vessels involves an orchestrated interaction among many mediators offering opportunity to modulate or inhibit the entire process. A two-component model for choroidal neovascularization is proposed. The vascular component of choroidal neovascularization is comprised of vascular endothelial cells, endothelial cell precursors, and pericytes. The extravascular component, which by histopathology appears to be both the source of angiogenic stimuli and often the largest component volumetrically, is comprised of inflammatory, glial and retinal pigment epithelial cells, and fibroblasts. Tissue damage can be caused by either component. Each component can be targeted through as variety of monotherapies. Combination therapies offer the possibility of attacking one component in more than one way or by attacking both components simultaneously. The two-component model of choroidal neovascularization can be used to evaluate the mechanism of action and possible interactions of these agents in a conceptual framework. Extension of these ideas can help guide development of new treatment agents and approaches.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.

            To examine the 7-month results for patients treated with combined photodynamic therapy (PDT) with verteporfin and intravitreal bevacizumab for choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). This is a retrospective series of 24 eyes with juxtafoveal or subfoveal CNV secondary to AMD. Patients were treated with PDT with verteporfin and 1.25 mg of intravitreal bevacizumab. All patients were naive to treatment and had either treatment within a 14-day interval. Main outcome measures were visual acuity stabilization (defined as no change or a gain in visual acuity) and retreatment rate. At the 7-month follow-up, 20 (83%) of 24 patients had stabilization of visual acuity. Sixteen eyes (67%) had improvement in visual acuity. Mean improvement in visual acuity (n = 24) was 2.04 Snellen lines. Fifteen eyes (63%) required only a single combined treatment for CNV resolution. There were no complications, including endophthalmitis, uveitis, and ocular hypertension. The results of this study suggest that combined treatment of PDT with verteporfin and intravitreal bevacizumab may be useful in treating neovascular AMD by reducing retreatment rates and improving visual acuity. Further investigation with large, controlled trials is warranted to outline the appropriate treatment paradigm for combination therapy.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation.

              To compare the long-term outcome of photodynamic therapy (PDT) with that of intravitreal bevacizumab (IVB) for myopic choroidal neovascularizations (mCNVs). 24 eyes were selected from 40 consecutive patients with mCNV, and the patients were divided into Group A, consisting of 12 eyes treated by PDT, and Group B, consisting of 12 eyes treated by 1.25 mg IVB. The age and best-corrected visual acuity (BCVA) were matched between the two groups. The BCVA, size of the chorioretinal atrophy surrounding the CNV (CRA), central foveal thickness (CFT) and CNV thickness were determined before and at 12 and 24 months after the treatment. The BCVA did not change after PDT but was significantly improved from 0.75+/-0.25 to 0.49+/-0.42 logMAR units at 12 months and to 0.50+/-0.38 logMAR units at 24 months after IVB. The CFT were significantly reduced in both groups at 12 and 24 months. The CRAs were larger in group A than in group B at 12 and 24 months, and their sizes were correlated with the BCVA. At 24 months, IVB is more effective than PDT in treating mCNV. The enlargement of the CRA might be related to the incomplete visual recovery after PDT.
                Bookmark

                Author and article information

                Journal
                Oman J Ophthalmol
                OJO
                Oman Journal of Ophthalmology
                Medknow Publications (India )
                0974-620X
                0974-7842
                Sep-Dec 2010
                : 3
                : 3
                : 159-160
                Affiliations
                Department of Ophthalmology, Shiley Eye Center, MC 0946, 9415, Campus Point Drive, Rm 217B, La Jolla, CA 92093, California
                Author notes
                Correspondence: Dr. Jay Kumar Chhablani, Department of Ophthalmology, Shiley Eye Center, MC 0946, 9415, Campus Point Drive, Rm 217B, La Jolla, CA 92093, California. E-mail: jay.chhablani@ 123456gmail.com
                Article
                OJO-3-159
                10.4103/0974-620X.71911
                2992170
                21120059
                b5e1e8ea-23d0-4024-aeb3-6d226cc0adae
                © Oman Journal of Ophthalmology

                This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                Categories
                Letters to the Editor

                Ophthalmology & Optometry
                Ophthalmology & Optometry

                Comments

                Comment on this article